LivaNova (NASDAQ:LIVN) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS

LivaNova (NASDAQ:LIVN) issued its quarterly earnings data on Wednesday. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.18, FiscalAI reports. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.34 million. During the same quarter in the prior year, the firm earned $1.05 EPS. The company’s revenue was up 10.8% on a year-over-year basis. LivaNova updated its FY 2026 guidance to 4.300-4.400 EPS.

Here are the key takeaways from LivaNova’s conference call:

• Q2 revenue rose 9.8% on a constant-currency basis to a record $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by growth in Cardiopulmonary and Epilepsy.
• LivaNova raised its 2026 revenue-growth outlook to 8%–9% and adjusted EPS guidance to $4.30–$4.40; Cardiopulmonary and Epilepsy growth expectations were also increased.
• The company is expanding oxygenator capacity through a new production line expected to go live in the second half of 2026 and a long-term Thermo Fisher agreement for a critical component, supporting potential market-share gains.
• Epilepsy momentum benefited from improved reimbursement, clinical evidence, higher realized pricing and a stronger patient funnel; management said new-patient implants are growing in existing accounts and through new account activations.
• Adjusted free-cash-flow guidance was reduced to $140 million–$160 million from $160 million–$180 million as capital spending rises to $135 million, while the OSA PMA supplement submission was pushed to between the second half of 2026 and the first half of 2027.

LivaNova Trading Down 2.7%

Shares of NASDAQ LIVN traded down $2.13 during mid-day trading on Thursday, hitting $76.01. The company’s stock had a trading volume of 422,825 shares, compared to its average volume of 774,976. The stock has a market cap of $4.18 billion, a price-to-earnings ratio of 38.96 and a beta of 0.86. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. LivaNova has a one year low of $47.13 and a one year high of $85.76. The company’s fifty day simple moving average is $79.54 and its 200-day simple moving average is $70.61.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its stake in LivaNova by 83.5% in the third quarter. Wellington Management Group LLP now owns 2,345,516 shares of the company’s stock valued at $122,858,000 after purchasing an additional 1,067,349 shares in the last quarter. Invesco Ltd. boosted its position in shares of LivaNova by 714.7% during the second quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after purchasing an additional 902,447 shares in the last quarter. Scopia Capital Management LP bought a new position in shares of LivaNova during the second quarter worth $36,657,000. Millennium Management LLC lifted its holdings in LivaNova by 22.4% during the third quarter. Millennium Management LLC now owns 2,969,814 shares of the company’s stock worth $155,559,000 after acquiring an additional 544,033 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in LivaNova by 29.9% during the fourth quarter. AQR Capital Management LLC now owns 2,155,142 shares of the company’s stock worth $132,606,000 after acquiring an additional 496,165 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Key Stories Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: LivaNova reported second-quarter earnings of $1.26 per share, above the $1.08 analyst consensus and up from $1.05 a year earlier. Revenue rose 10.8% year over year to $390.6 million, exceeding estimates of $380.3 million. Growth in the Cardiopulmonary and Epilepsy businesses helped drive margin improvement. LivaNova Q2 Earnings and Revenues Beat Estimates, 2026 Outlook Raised
• Positive Sentiment: Management raised its fiscal 2026 adjusted EPS outlook to $4.30-$4.40, above the prior consensus estimate of $4.15. Revenue guidance remains approximately $1.5 billion, generally in line with expectations. LivaNova Raises Guidance on Q2 Beats
• Positive Sentiment: Needham raised its price target on LIVN from $81 to $93 and maintained a “buy” rating, indicating confidence that earnings growth and the improved outlook can support additional upside. Analyst Price Target Report
• Negative Sentiment: The share-price pullback may reflect valuation concerns and profit-taking following a recent 52-week high. LivaNova trades at roughly 39 times earnings, so investors may be demanding continued execution and further upward revisions despite the quarterly beat.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a research note on Wednesday. Mizuho upped their price objective on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. KeyCorp upped their price objective on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of LivaNova in a research note on Tuesday. Finally, Robert W. Baird lowered their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $83.50.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.